Rheumatoid Arthritis
Feature
Humira biosimilars: Five things to know
The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...
From the Journals
Antidrug antibody effects compared across RA biologics
The presence of antidrug antibodies was associated with a diminished response to biologic disease-modifying antirheumatic drugs in a prospective...
Feature
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Experts in rheumatology, dermatology, and gastroenterology assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic...
From the Journals
Methotrexate does not impair sperm quality, small study finds
The findings provide reassurance that men can start methotrexate therapy while actively pursuing parenthood.
Feature
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
SmithRx, which bills itself as “next-generation pharmacy benefits management,” announced that it will offer Yusimry to its members at a discount...
Conference Coverage
AI efforts make strides in predicting progression to RA
Two independent efforts to use artificial intelligence to predict the development of early RA from patients with signs and symptoms not meeting...
Conference Coverage
RA and demyelinating disease: No consistent link to TNFi
Patients with rheumatoid arthritis who take a tumor necrosis factor inhibitor do not appear to have a consistent and significant risk for...
Conference Coverage
High-intensity interval training has sustainable effects in patients with inflammatory arthritis
Patients in a randomized trial improved their cardiorespiratory fitness, but the positive response did not coincide with changes in pain or...
Feature
Why not both? Dual biologics for treatment-resistant RA and PsA
Previous clinical trials of dual biologic therapies have raised safety issues, but more recent, promising findings from clinical trials and case...
Feature
Is ChatGPT a friend or foe of medical publishing?
Experts agree that the use of AI tools is here to stay. “This is going to become a common tool. I don’t think there’s a way out of that at this...
Conference Coverage
Studies reveal nuances in efficacy, MACE risk between JAKi and TNFi
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs. TNF inhibitors, as well as their efficacy...